Mr. Hodges was the founder and President of Metrics, Inc. Since founding Metrics in 1994, Hodges oversaw its transition from a start-up analytical laboratory with four employees to one of the Southeast’s premier pharmaceutical development laboratories with more than 350 employees. Throughout his tenure, Metrics experienced double-digit annual revenue growth. Metrics, Inc. was sold in 2012 to the Mayne Pharma Group, Ltd. of Melbourne, Australia. Prior to starting Metrics, Hodges worked for 11 years at Burroughs Wellcome Co. (which eventually became part of GlaxoSmithKline) in the development and validation of analytical methods. Since the sale of Metrics, Mr. Hodges has participated in several startup technology companies where he participates as a board chairman or LLC manager, including Chesson Laboratory Associates, XComP, Inc., and Nano Ventures, LLC. He is also a manager in Kaio Therapy, LLC, an immuno-oncology company where he helps lead their technical development. Hodges holds BS and MS degrees in chemistry and analytical chemistry from East Carolina University.
Before joining Perfusio, Peter Geiger served as Chief Financial Officer at DSM Pharmaceuticals, a contract pharmaceutical manufacturing company producing $2 billion worth of consumer products annually. Mr. Geiger brings to Perfusio significant financial leadership in health services start-ups, including serving as Managing General Partner of Geiger Investments Ltd., where he applies his expertise in company valuation to generate above-market returns for partners. In addition to an undergraduate degree in Behavioral Neuroscience from Lehigh University, Mr. Geiger graduated with honors from the Wharton School of Business at the University of Pennsylvania with an MBA in finance and strategic management.
Chief Science and Technical Officer and Co-Founder
A highly regarded optical physicist, Dr. Chen began creating Perfusio’s revolutionary technology in 2008. With expertise in imaging algorithm and visualization, Dr. Chen was one of the first to recognize the enormous clinical potential for real-time analysis of perfusion and blood flow. He developed the software that powers the company’s Complex Angiography and Perfusion Analysis (CAPA) platform and is co-inventor of its Multi-Spectral Physiologic Visualization (MSPV) technology. His leadership was critical for IP strategy and the patent application process and will lead the company to future applications, designs, and IP expansions. Dr. Chen earned his doctorate in Biomedical Physics from East Carolina University (ECU), which led to a significant career in optical imaging of turbid biological medium and publication of numerous papers in peer-reviewed scientific journals. After serving in ECU’s Physics and Engineering Departments, he is now an adjunct associate professor there. Dr. Chen is a member of the National Academy of Inventors and currently holds six patents, with more than 30 additional applications under review in the U.S. and internationally.
An internationally renowned cardiovascular surgeon, Dr. Bruce Ferguson is co-creator of Perfusio’s Multi-Spectral Physiologic Visualization (MSPV) technology and was instrumental in guiding the development of clinical applications and physician adoption of the platform. He was a pioneer in near-infrared fluorescence (NIRF) imaging in cardiac surgery and performed over 1,000 cases using the modality. As an early adopter of data-driven and quality-outcomes medicine with extensive experience
In clinical databases, Dr. Ferguson is leading Perfusio’s First in Person Certes (FIRST) Study, a multicenter clinical use study of Certes™ across multiple surgical specialties and applications. Dr. Ferguson has been extramurally funded by Health and Human Services entities continuously since 1989 at Washington University in St. Louis, Duke University, Louisiana State University in New Orleans, and the East Carolina University Brody School of Medicine. He is also Principal Investigator on Perfusio’s three STTR and SBIR grant projects to date and led the research required for FDA 510(k) Class II approval of its first form factor, Certes. Dr. Ferguson is a member of the National Academy of Inventors and currently holds 14 patents.
Mr. Alvarez has enjoyed a distinguished career and brings expertise in engineering operations and leadership in Medical Device product and service development for patients and physicians in multiple healthcare specialties. Prior to joining Perfusio, he was Senior Director of Engineering Operations and Quality at BIONIK, Inc., a global rehabilitation robotics manufacturer with data-driven robotic-assisted therapy solutions for patients with neurological impairments. Before that, he spent more than a decade steeped in Olympus Surgical Technologies America, where he managed cross-functional engineering teams and led operations and value stream initiatives for products in urology, gynecology, ENT, and general surgery markets. He is skilled in ISO 13485 and 21CFR820 certification and standards, quality management systems, design controls, lean manufacturing techniques, and organization development. He has an MBA from Kettering University with an undergraduate degree in biomedical/biomechanics engineering from the University of Rochester.
Mr. Tawil joins Perfusio’s team with 25+ years of experience in sales and business development in the medical device industry. Through his broad experience in tissue regeneration, soft tissue repair, biologic tissue products, medical instruments, and imaging technologies, he has developed a creative approach to commercializing new technologies in the medical device market. Most recently, Mr. Tawil served as the Vice President of Sales and Business Development for Corius Tissue Regeneration, part of Medline Industries Inc. There, he constructed a national salesforce and commercialization strategy for tissue regeneration technologies for wound care tailored to physicians’ needs. Mr. Tawil also worked 15 years with LifeCell Corporation, where he was instrumental in identifying new markets and developing sales and marketing strategies to advance biologic tissue from new technology to standard of care in the plastic surgery and general surgery specialties. He has extensive experience building and leading sales teams that deliver business growth on a national basis. Mr. Tawil enters this role with a successful history in salesforce leadership and a creative approach that brings new products to the forefront of clinical practice.
Mr. Makalinaw brings over 15 years of cybersecurity experience to our team, most recently serving in a leadership role as a Security Compliance Officer at ARMUS, a trusted partner of Perfusio. Previously, he consulted with multiple healthcare companies on cybersecurity, risk and compliance. Mr. Makalinaw holds numerous certifications including Certified Information Systems Auditor (CISA), Certified Information Systems Security Professional (CISSP), and Certified Data Privacy Solutions Engineer (CDPSE).